The effect of plasma from muscle-specific tyrosine kinase myasthenia patients on regenerating endplates

American Journal of Pathology

Volumn 175, Issue 4, 2009, Pages 1536-1544

  Ter Beek, W Pascale ^a   Martínez Martínez, Pilar ^c   Losen, Mario ^c   De Baets, Marc H ^c,d   Wintzen, Axel R ^b   Verschuuren, Jan J G M ^b   Niks, Erik H ^b   Van Duinen, Sjoerd G ^b   Vincent, Angela ^e   Molenaar, Peter C ^a,c  

^a Neurophysiology Section   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d HASSELT UNIVERSITY   (Belgium)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BUNGAROTOXIN; CALCIUM ION; CHOLINERGIC RECEPTOR; IODINE 125; NOTEXIN; PROTEIN TYROSINE KINASE; TUBOCURARINE CHLORIDE;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CHILD; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; MUSCLE CONTRACTION; MUSCLE REGENERATION; MYASTHENIA GRAVIS; NERVE ENDING; NERVE REGENERATION; NONHUMAN; PLASMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION;

EID: 73549091486     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.090040     Document Type: Article

References (49)

1. Patrick J, Lindstrom J: Autoimmune response to acetylcholine receptor. Science 1973, 180:871-872
2. Drachman DB: Myasthenia gravis: immunobiology of a receptor disorder. Trends Neurosci 1983, 6:446-451
3. Vincent A: Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol 2002, 2:797-804
4. Losen M, Martinez-Martinez P, Phernambucq M, Schuurman J, Parren PW, De Baets MH: Treatment of myasthenia gravis by preventing acetylcholine receptor modulation. Ann NY Acad Sci 2008, 1132:174-179
5. Heinemann S, Merlie J, Lindstrom J: Modulation of acetylcholine receptor in rat diaphragm by anti-receptor sera. Nature 1978, 274:65-68
6. Leite MI, Jacob S, Viegas S, Cossins J, Clover L, Morgan BP, Beeson D, Willcox N, Vincent A: IgG1 antibodies to acetylcholine receptors in "seronegative" myasthenia gravis. Brain 2008, 131(Pt 7):1940-1952
7. Drachman DB, de Silva S, Ramsay D, Pestronk A: Humoral pathogenesis of myasthenia gravis. Ann NY Acad Sci 1987, 505:90-105
8. Mossman S, Vincent A, Newsom-Davis J: Myasthenia gravis without acetylcholine-receptor antibody: a distinct disease entity. Lancet 1986, 1:116-119
9. Burges J, Vincent A, Molenaar PC, Newsom-Davis J, Peers C, Wray D: Passive transfer of seronegative myasthenia gravis to mice. Muscle Nerve 1994, 17:1393-1400
10. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A: Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001, 7:365-368
11. Niks EH, Kuks JB, Verschuuren JJ: Epidemiology of myasthenia gravis with anti-muscle specific kinase antibodies in The Netherlands. J Neurol Neurosurg Psychiatry 2007, 78:417-418
12. Evoli A, Tonali PA, Padua L, Monaco ML, Scuderi F, Batocchi AP, Marino M, Bartoccioni E: Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003, 126:2304-2311
13. Farrugia ME, Robson MD, Clover L, Anslow P, Newsom-Davis J, Kennett R, Hilton-Jones D, Matthews PM, Vincent A: MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis. Brain 2006, 129:1481-1492
14. Lavrnic D, Losen M, Vujic A, De Baets M, Hajdukovic LJ, Stojanovic V, Trikic R, Djukic P, Apostolski S: The features of myasthenia gravis with autoantibodies to MuSK. J Neurol Neurosurg Psychiatry 2005, 76:1099-1102
15. Vincent A, McConville J, Farrugia ME, Bowen J, Plested P, Tang T, Evoli A, Matthews I, Sims G, Dalton P, Jacobson L, Polizzi A, Blaes F, Lang B, Beeson D, Willcox N, Newsom-Davis J, Hoch W: Antibodies in myasthenia gravis and related disorders. Ann NY Acad Sci 2003, 998:324-335
16. Niks EH, van Leeuwen Y, Leite MI, Dekker FW, Wintzen AR, Wirtz PW, Vincent A, van Tol MJ, Jol-van der Zijde CM, Verschuuren JJ: Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1. J Neuroimmunol 2008, 195:151-156
17. van der Neut Kolfschoten M, Schuurman J, Losen M, Bleeker WK, Martinez-Martinez P, Vermeulen E, den Bleker TH, Wiegman L, Vink T, Aarden LA, De Baets MH, van de Winkel JG, Aalberse RC, Parren PW: Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007, 317:1554-1557
18. Gautam M, Noakes PG, Mudd J, Nichol M, Chu GC, Sanes JR, Merlie JP: Failure of postsynaptic specialization to develop at neuromuscular junctions of rapsyn-deficient mice. Nature 1995, 377:232-236
19. McMahan UJ: The agrin hypothesis. Cold Spring Harb Symp Quant Biol 1990, 55:407-418
20. Weatherbee SD, Anderson KV, Niswander LA: LDL-receptor-related protein 4 is crucial for formation of the neuromuscular junction. Development 2006, 133:4993-5000
21. Kim N, Stiegler AL, Cameron TO, Hallock PT, Gomez AM, Huang JH, Hubbard SR, Dustin ML, Burden SJ: Lrp4 is a receptor for Agrin and forms a complex with MuSK. Cell 2008, 135:334-342
22. DeChiara TM, Bowen DC, Valenzuela DM, Simmons MV, Poueymirou WT, Thomas S, Kinetz E, Compton DL, Rojas E, Park JS, Smith C, DiStefano PS, Glass DJ, Burden SJ, Yancopoulos GD: The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo. Cell 1996, 85:501-512
23. Kong XC, Barzaghi P, Ruegg MA: Inhibition of synapse assembly in mammalian muscle in vivo by RNA interference. EMBO Rep 2004, 5:183-188
24. Bezakova G, Rabben I, Sefland I, Fumagalli G, Lomo T: Neural agrin controls acetylcholine receptor stability in skeletal muscle fibers. Proc Natl Acad Sci USA. 2001, 98:9924-9929
25. Grubb BD, Harris JB, Schofield IS: Neuromuscular transmission at newly formed neuromuscular junctions in the regenerating soleus muscle of the rat. J Physiol 1991, 441:405-421
26. Jaretzki A, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB: Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000, 55:16-23
27. McConville J, Farrugia ME, Beeson D, Kishore U, Metcalfe R, Newsom-Davis J, Vincent A: Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 2004, 55:580-584
28. Molenaar PC, Oen BS, Plomp JJ, Van Kempen GT, Jennekens FG, Hesselmans LF: A nonimmunogenic myasthenia gravis model and its application in a study of transsynaptic regulation at the neuromuscular junction. Eur J Pharmacol 1991, 196:93-101
29. Molenaar PC: A relative weak leg muscle in the rolling Nagoya mouse as a model for Lambert-Eaton myasthenic syndrome. J Neuroimmunol. 2008, 201-202:166-171
30. Losen M, Stassen MH, Martinez-Martinez P, Machiels BM, Duimel H, Frederik P, Veldman H, Wokke JH, Spaans F, Vincent A, De Baets MH: Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis. Brain 2005, 128:2327-2337
31. Martinez-Martinez P, Losen M, Duimel H, Frederik P, Spaans F, Molenaar P, Vincent A, De Baets MH: Overexpression of rapsyn in rat muscle increases acetylcholine receptor levels in chronic experimental autoimmune myasthenia gravis. Am J Pathol 2007, 170:644-657
32. Jirmanova I, Thesleff S: Ultrastructural study of experimental muscle degeneration and regeneration in the adult rat. Z Zellforsch Mikrosk Anat 1972, 131:77-97
33. Wood SJ, Slater CR: Safety factor at the neuromuscular junction. Prog Neurobiol 2001, 64:393-429
34. 2+ channel. Ann NY Acad Sci 2003, 998:29-32
35. Zhu D, Yang Z, Luo Z, Luo S, Xiong WC, Mei L: Muscle-specific receptor tyrosine kinase endocytosis in acetylcholine receptor clustering in response to agrin. J Neurosci 2008, 28:1688-1696
36. Salpeter MM, Loring RH: Nicotinic acetylcholine receptors in vertebrate muscle: properties, distribution and neural control. Prog Neurobiol 1985, 25:297-325
37. Sheng ZH, Zhang H, Barchi RL, Kallen RG: Molecular cloning and functional analysis of the promoter of rat skeletal muscle voltagesensitive sodium channel subtype 2 (rSkM2): evidence for musclespecific nuclear protein binding to the core promoter. DNA Cell Biol 1994, 13:9-23
38. Shyng SL, Salpeter MM: Degradation rate of acetylcholine receptors inserted into denervated vertebrate neuromuscular junctions. J Cell Biol 1989, 108:647-651
39. Shyng SL, Salpeter MM: Effect of reinnervation on the degradation rate of junctional acetylcholine receptors synthesized in denervated skeletal muscles. J Neurosci 1990, 10:3905-3915
40. Chevessier F, Faraut B, Ravel-Chapuis A, Richard P, Gaudon K, Bauche S, Prioleau C, Herbst R, Goillot E, Ioos C, Azulay JP, Attarian S, Leroy JP, Fournier E, Legay C, Schaeffer L, Koenig J, Fardeau M, Eymard B, Pouget J, Hantai D: MUSK, a new target for mutations causing congenital myasthenic syndrome. Hum Mol Genet 2004, 13:3229-3240
41. Barrett-Jolley R, Byrne N, Vincent A, Newsom-Davis J: Plasma from patients with seronegative myasthenia gravis inhibit nAChR responses in the TE671/RD cell line. Pflugers Arch 1994, 428:492-498
42. Farrugia ME, Bonifati DM, Clover L, Cossins J, Beeson D, Vincent A: Effect of sera from AChR-antibody negative myasthenia gravis patients on AChR and MuSK in cell cultures. J Neuroimmunol 2007, 185:136-144
43. Jha S, Xu K, Maruta T, Oshima M, Mosier DR, Atassi MZ, Hoch W: Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (MuSK). J Neuroimmunol 2006, 175:107-117
44. Cole RN, Reddel SW, Gervasio OL, Phillips WD: Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann Neurol 2008, 63:782-789
45. Balice-Gordon RJ, Breedlove SM, Bernstein S, Lichtman JW: Neuromuscular junctions shrink and expand as muscle fiber size is manipulated: in vivo observations in the androgen-sensitive bulbocavernosus muscle of mice. J Neurosci 1990, 10:2660-2671
46. Lichtman JW, Magrassi L, Purves D: Visualization of neuromuscular junctions over periods of several months in living mice. J Neurosci 1987, 7:1215-1222
47. Selcen D, Fukuda T, Shen XM, Engel AG: Are MuSK antibodies the primary cause of myasthenic symptoms? Neurology 2004, 62: 1945-1950
48. Shiraishi H, Motomura M, Yoshimura T, Fukudome T, Fukuda T, Nakao Y, Tsujihata M, Vincent A, Eguchi K: Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol 2005, 57:289-293
49. Lindstrom J: Is "seronegative" MG explained by autoantibodies to MuSK? Neurology 2004, 62:1920-1921